1349. Safety and Pharmacokinetics (PK) of the Respiratory Syncytial Virus (RSV) Polymerase Inhibitor, ALS-8176, in Otherwise Healthy Infants Hospitalized with Acute RSV Infection
Session: Poster Abstract Session: Clinical Trials
Friday, October 28, 2016
Room: Poster Hall
Posters
  • IDSA 2016 - Poster - Blinded 503 Data - FINAL.pdf (423.0 kB)
  • Background: ALS-8176 is a prodrug of the nucleoside analog, ALS-8112, the triphosphate of which is a potent inhibitor of the RSV polymerase.

     

    Objective: Determine safety of single/multiple ascending doses (SAD, MAD) of ALS-8176 and PK of ALS-8112 in RSV infected infants.

    Methods: Randomized, double blind, placebo-controlled SAD, MAD study in otherwise healthy 1-12 month old patients (pts) hospitalized with RSV infection. The cohort size and dose for the first SAD cohort was prespecified. The makeup of all other cohorts was determined by an Independent Data Monitoring Committee (IDMC), which regularly reviewed data.   Safety and sparse PK were collected for 7 (SAD) and 28 (MAD) days post randomization.  PK was analyzed by population PK methods.      

    Results: 112 (70 SAD:42 MAD) infants have been randomized into 7 SAD, MAD regimens (Figure).  Four unrelated serious adverse events (AEs) have been reported in the SAD (phlebitis, tachycardia, respiratory failure) and MAD (lymphadenitis).   No study drug discontinuations have occurred and all treatment-emergent AEs (N=114) were mild (N=91) or moderate (N=22) except respiratory failure, which was severe. Blinded AEs reported in ≥3 pts were:

    AE

    SAD

    MAD

    Thrombocytosis

    9

    4

    Diarrhea

    4

    6

    Diaper Rash

    1

    7

    Vomiting

    5

    2

    Aspartate transaminase increased

    3

    4

    Rash

    2

    4

    Eczema

    1

    4

    Creatine kinase increased

    3

    1

    Tachycardia

    4

    0

    Conjunctivitis

    2

    1

    Leukocytosis

    2

    1

    No concerning trends in AEs, laboratories, vital signs, physical examinations or electrocardiograms were identified in the blinded data or from IDMC reports.  Available unblinded safety/efficacy data will be presented.

    ALS-8176 was rapidly converted to ALS-8112 and the PK was consistent with predictions from modeling and simulation in adults.  ALS-8112 plasma exposures increased in a less than dose proportional manner with increasing ALS-8176 doses.  No accumulation was noted.  Body weight, renal function, and fed/fasted state were included as model covariates influencing PK.

    Conclusion: In hospitalized infants, ALS-8176 was well-tolerated and demonstrated predictable PK following single doses up to 25 mg/kg and multiple doses up to a 30 mg/kg loading dose followed by 6 mg/kg maintenance doses.  Further evaluation of the efficacy, safety and PK of ALS-8176 in pediatric pts is warranted.

    FIGURE

    Adam Finn, MD, PhD1, Michael Fayon, MD PhD2, Jolanta Bernatoniene, MD PhD3, Kathia Luciani, MD4, Rattapon Uppala, MD5, John Fry, BS, RGN6, Sushmita Chanda, PhD6, Patrick Smith, PharmD Candidate7, Keith Nieforth, PhD7, Kashyap Patel, PhD8, Abbie Oey, BA6, Julian Symons, D. Phil.6, Qingling Zhang, PhD6, Lawrence Blatt, PhD6, Leonid Beigelman, PhD6 and Matthew Mcclure, MD6, (1)University of Bristol, Bristol, United Kingdom, (2)CHU de Bordeaux, Bordeaux, France, (3)University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, (4)Hospital de Especialidades Pediátricas de la Caja de Seguro Social, Panamá, Panama, (5)Khon Kaen University, Khon Kaen, Thailand, (6)Alios BioPharma, South San Francisco, CA, (7)D3 Medicine, Parsippany, NJ, (8)Monash University, Parkville, Australia

    Disclosures:

    A. Finn, Alios BioPharma: Consultant , Consulting fee

    M. Fayon, Alios BioPharma: Investigator , Research support

    J. Bernatoniene, Alios BioPharma: Investigator , Research support

    K. Luciani, Alios BioPharma: Investigator , Research support

    R. Uppala, Alios BioPharma: Investigator , Research support

    J. Fry, Alios BioPharma: Employee , Salary

    S. Chanda, Alios BioPharma: Employee , Salary

    P. Smith, Alios BioPharma: Consultant , Consulting fee

    K. Nieforth, Alios BioPharma: Consultant , Consulting fee

    K. Patel, Alios BioPharma: Consultant , Consulting fee

    A. Oey, Alios BioPharma: Employee , Salary

    J. Symons, Alios BioPharma: Employee , Salary

    Q. Zhang, Alios BioPharma: Employee , Salary

    L. Blatt, Alios BioPharma: Employee , Salary

    L. Beigelman, Alios BioPharma: Employee , Salary

    M. Mcclure, Alios BioPharma: Employee , Salary

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.